financetom
Business
financetom
/
Business
/
Hyundai to launch $3 billion India IPO next week at 1,865-1,960 rupees per share, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hyundai to launch $3 billion India IPO next week at 1,865-1,960 rupees per share, sources say
Oct 10, 2024 11:53 PM

By Aditya Kalra and Scott Murdoch

NEW DELHI/HONG KONG (Reuters) - Hyundai Motor India's IPO will open next week for subscriptions and will likely be priced in the range of 1,865 to 1,960 rupees ($22 to $23) per share, sources said on Tuesday, valuing the automaker at up to $19 billion in the country's biggest stock offering this year.

The India IPO will be Hyundai's first stock market listing outside South Korea. In India, it will also mark the first carmaker to go public in two decades since Maruti Suzuki in 2003, and comes just after Indian stock markets touched record highs and saw many companies making debuts.

The $3 billion IPO will open for subscriptions for big institutional investors on Oct. 14, and invite bids from retail and other categories during Oct. 15-17, said three sources with direct knowledge, who declined to be named as the discussions are confidential.

At the upper end of the price band, the company will roughly be valued at $19 billion, the sources said, adding the stock is set to start trading in Mumbai on Oct. 22.

Hyundai did not immediately respond to Reuters queries.

Hyundai is India's second largest automaker after Maruti and is looking to reclaim market share from domestic rivals by expanding its SUV lineup.

It also plans to launch its first India-made electric vehicle early next year and introduce at least two gasoline-powered models tailored to the market starting in 2026.

Hyundai will not issue new shares in the IPO which will involve its South Korean parent selling up to 17.5% of its stake in the wholly owned unit to retail and other investors via a so-called "offer for sale" route.

The South Korean automaker said on Tuesday it will still hold 670 million shares in Hyundai Motor India, or an 82.5% stake, after the IPO.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DigitalOcean Closes $625 Million Notes Offering
DigitalOcean Closes $625 Million Notes Offering
Aug 18, 2025
09:24 AM EDT, 08/18/2025 (MT Newswires) -- DigitalOcean ( DOCN ) said Monday that it has closed a $625 million offering of 0% convertible senior notes due Aug. 15, 2030. The total size of the offering includes the exercise of $75 million in initial purchasers' options, the company said. DigitalOcean ( DOCN ) said it estimates the offering will generate...
Impact BioMedical Receives US Patent for Method for Controlling Infectious Diseases
Impact BioMedical Receives US Patent for Method for Controlling Infectious Diseases
Aug 18, 2025
09:23 AM EDT, 08/18/2025 (MT Newswires) -- Impact BioMedical ( IBO ) said Monday that the US Patent and Trademark Office has issued a patent related to its composition and method for controlling infectious diseases with functional fragrances, which was developed within the company's 3F technology platform. The biotech company said the patent includes compositions and formulations of fragrances produced...
Myriad Genetics Names Ben Wheeler CFO
Myriad Genetics Names Ben Wheeler CFO
Aug 18, 2025
09:24 AM EDT, 08/18/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) said Monday that it has appointed Ben Wheeler as chief financial officer, effective Aug. 16. Wheeler, who has been Myriad's CFO for operations since 2022, will succeed Scott Leffler, the company said. Leffler will remain with the company in a consulting role serving the CEO and the board...
Capricor Therapeutics' Phase 1 Trial for Exosome-Based Vaccine Doses First Subjects
Capricor Therapeutics' Phase 1 Trial for Exosome-Based Vaccine Doses First Subjects
Aug 18, 2025
09:25 AM EDT, 08/18/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Monday the first subjects have been dosed in a phase 1 trial evaluating its StealthX exosome-based vaccine. The study is funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases under the US Department of Health and Human Services' Project NextGen, Capricor said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved